(CDNA) CareDx - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 942m USD | Total Return: 5.7% in 12m

Transplant Testing, Gene Expression, HLA Typing, Software
Total Rating 38
Safety 38
Buy Signal -0.27
Diagnostics & Research
Industry Rotation: +10.3
Market Cap: 942M
Avg Turnover: 10.1M USD
ATR: 4.84%
Peers RS (IBD): 20.8
Risk 5d forecast
Volatility77.4%
Rel. Tail Risk-16.2%
Reward TTM
Sharpe Ratio0.34
Alpha-32.13
Character TTM
Beta1.016
Beta Downside-0.040
Drawdowns 3y
Max DD65.96%
CAGR/Max DD0.43
EPS (Earnings per Share) EPS (Earnings per Share) of CDNA over the last years for every Quarter: "2021-03": 0.14, "2021-06": 0.11, "2021-09": 0.07, "2021-12": -0.03, "2022-03": -0.13, "2022-06": -0.13, "2022-09": -0.06, "2022-12": -0.07, "2023-03": -0.11, "2023-06": -0.18, "2023-09": -0.18, "2023-12": -0.17, "2024-03": -0.03, "2024-06": 0.25, "2024-09": 0.14, "2024-12": 0.18, "2025-03": 0.1, "2025-06": 0.1, "2025-09": 0.28, "2025-12": 0.12,
EPS CAGR: 53.34%
EPS Trend: 77.2%
Last SUE: 0.96
Qual. Beats: 3
Revenue Revenue of CDNA over the last years for every Quarter: 2021-03: 67.4, 2021-06: 74.188, 2021-09: 75.589, 2021-12: 79.22, 2022-03: 79.416, 2022-06: 80.634, 2022-09: 79.359, 2022-12: 82.384, 2023-03: 77.262, 2023-06: 70.301, 2023-09: 67.192, 2023-12: 65.569, 2024-03: 72.049, 2024-06: 92.274, 2024-09: 82.883, 2024-12: 86.579, 2025-03: 84.685, 2025-06: 86.679, 2025-09: 100.055, 2025-12: 108.386,
Rev. CAGR: 8.65%
Rev. Trend: 58.1%
Last SUE: 0.63
Qual. Beats: 0

Warnings

Interest Coverage Ratio -37.5 is critical

Altman Z'' -10.51 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: CDNA CareDx

CareDx, Inc. (CDNA) offers diagnostic solutions for transplant patients, focusing on organ health outcomes. The companys primary products include donor-derived cell-free DNA (dd-cfDNA) tests like AlloSure for kidney, heart, and lung transplant patients. These tests are part of a broader trend in personalized medicine aimed at improving post-transplant care.

CareDx also provides gene expression profiling, such as AlloMap Heart, and tissue analysis solutions like HistoMap Kidney. Additionally, the company offers monitoring tests for conditions like acute myeloid leukemia (AlloHeme) and various software solutions for transplant patient management (e.g., Ottr, XynQAPI). The biotechnology sector, in which CareDx operates, is characterized by significant investments in research and development to bring novel diagnostic and therapeutic tools to market.

Further offerings include Human Leukocyte Antigen (HLA) typing products (QTYPE, Olerup SSP, AlloSeq Tx) and chimerism testing for stem cell transplant recipients (AlloSeq HCT). CareDxs business model relies on developing and commercializing advanced diagnostic tests and related software, often involving partnerships with other technology providers like Illumina, Inc. To gain deeper insights into CareDxs financial performance and competitive landscape, consider exploring its detailed financials on platforms like ValueRay.

Headlines to Watch Out For
  • AlloSure Kidney sales growth drives revenue
  • Reimbursement policy changes impact test profitability
  • Transplant patient volumes affect diagnostic demand
  • Competition from new diagnostic technologies
  • Regulatory scrutiny of laboratory developed tests
Piotroski VR‑10 (Strict) 6.0
Net Income: -21.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.40 > 1.0
NWC/Revenue: 44.04% < 20% (prev 78.63%; Δ -34.59% < -1%)
CFO/TA 0.10 > 3% & CFO 42.0m > Net Income -21.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.86 > 1.5 & < 3
Outstanding Shares: last quarter (51.1m) vs 12m ago -12.19% < -2%
Gross Margin: 67.20% > 18% (prev 0.67%; Δ 6.65k% > 0.5%)
Asset Turnover: 84.00% > 50% (prev 67.97%; Δ 16.03% > 0%)
Interest Coverage Ratio: -37.54 > 6 (EBITDA TTM -120k / Interest Expense TTM 547k)
Altman Z'' -10.51
A: 0.40 (Total Current Assets 257.1m - Total Current Liabilities 89.8m) / Total Assets 413.2m
B: -1.78 (Retained Earnings -735.4m / Total Assets 413.2m)
C: -0.05 (EBIT TTM -20.5m / Avg Total Assets 452.1m)
D: -6.73 (Book Value of Equity -740.8m / Total Liabilities 110.1m)
Altman-Z'' Score: -10.51 = D
Beneish M -3.15
DSRI: 0.58 (Receivables 42.6m/64.6m, Revenue 379.8m/333.8m)
GMI: 1.00 (GM 67.20% / 67.14%)
AQI: 1.47 (AQ_t 0.24 / AQ_t-1 0.17)
SGI: 1.14 (Revenue 379.8m / 333.8m)
TATA: -0.15 (NI -21.4m - CFO 42.0m) / TA 413.2m)
Beneish M-Score: -3.15 (Cap -4..+1) = AA
What is the price of CDNA shares? As of April 09, 2026, the stock is trading at USD 17.92 with a total of 703,580 shares traded.
Over the past week, the price has changed by +0.28%, over one month by +1.01%, over three months by +4.07% and over the past year by +5.66%.
Is CDNA a buy, sell or hold? CareDx has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CDNA.
  • StrongBuy: 4
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CDNA price?
Analysts Target Price 24.8 38.4%
CareDx (CDNA) - Fundamental Data Overview as of 07 April 2026
P/E Forward = 74.0741
P/S = 2.4795
P/B = 3.0939
P/EG = -0.12
Revenue TTM = 379.8m USD
EBIT TTM = -20.5m USD
EBITDA TTM = -120k USD
Long Term Debt = 26.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.43m USD (from shortTermDebt, two quarters ago)
Debt = 32.6m USD (corrected: LT Debt 26.2m + ST Debt 6.43m)
Net Debt = -144.6m USD (recalculated: Debt 32.6m - CCE 177.2m)
Enterprise Value = 797.1m USD (941.7m + Debt 32.6m - CCE 177.2m)
Interest Coverage Ratio = -37.54 (Ebit TTM -20.5m / Interest Expense TTM 547k)
EV/FCF = 21.86x (Enterprise Value 797.1m / FCF TTM 36.5m)
FCF Yield = 4.57% (FCF TTM 36.5m / Enterprise Value 797.1m)
FCF Margin = 9.60% (FCF TTM 36.5m / Revenue TTM 379.8m)
Net Margin = -5.62% (Net Income TTM -21.4m / Revenue TTM 379.8m)
Gross Margin = 67.20% ((Revenue TTM 379.8m - Cost of Revenue TTM 124.6m) / Revenue TTM)
Gross Margin QoQ = 66.62% (prev 68.71%)
Tobins Q-Ratio = 1.93 (Enterprise Value 797.1m / Total Assets 413.2m)
Interest Expense / Debt = 1.68% (Interest Expense 547k / Debt 32.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.2m (EBIT -20.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 257.1m / Total Current Liabilities 89.8m)
Debt / Equity = 0.11 (Debt 32.6m / totalStockholderEquity, last quarter 303.1m)
 Debt / EBITDA = 1.20k (out of range, set to none) (Net Debt -144.6m / EBITDA -120k)
 Debt / FCF = -3.97 (Net Debt -144.6m / FCF TTM 36.5m)
Total Stockholder Equity = 330.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.72% (Net Income -21.4m / Total Assets 413.2m)
RoE = -6.47% (Net Income TTM -21.4m / Total Stockholder Equity 330.2m)
RoCE = -5.76% (EBIT -20.5m / Capital Employed (Equity 330.2m + L.T.Debt 26.2m))
 RoIC = -4.91% (negative operating profit) (NOPAT -16.2m / Invested Capital 330.2m)
 WACC = 9.28% (E(941.7m)/V(974.4m) * Re(9.56%) + D(32.6m)/V(974.4m) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.53%
[DCF] Terminal Value 65.05% ; FCFF base≈34.5m ; Y1≈22.7m ; Y5≈10.4m
[DCF] Fair Price = 6.09 (EV 167.4m - Net Debt -144.6m = Equity 312.0m / Shares 51.2m; r=9.28% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 77.24 | EPS CAGR: 53.34% | SUE: 0.96 | # QB: 3
Revenue Correlation: 58.14 | Revenue CAGR: 8.65% | SUE: 0.63 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.17 | Chg7d=+0.000 | Chg30d=-0.067 | Revisions Net=-4 | Analysts=6
EPS current Year (2026-12-31): EPS=0.69 | Chg7d=+0.000 | Chg30d=-0.198 | Revisions Net=-4 | Growth EPS=+19.5% | Growth Revenue=+13.8%
EPS next Year (2027-12-31): EPS=1.09 | Chg7d=+0.000 | Chg30d=+0.032 | Revisions Net=+0 | Growth EPS=+57.5% | Growth Revenue=+11.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle